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Abstract 
Chromophobe kidney cancer accounts for approximately 5% of cases of renal cell carcinoma 
(RCC). While the genetics of clear cell RCC has been a major focus of research, little is known 
about the biology of chromophobe tumors. There is ample preclinical rationale for the use of 
targeted therapy in clear cell tumors, and agents targeting the VHL/HIF pathway are now 
widely used in clinical practice. However, there is limited experience with targeted agents in 
non-clear cell tumors. Recently, a few case reports have emerged which report the use of 
mTOR inhibitors in chromophobe tumors. Here, we report our experience with targeted 
therapy in a patient with advanced chromophobe RCC who had a durable partial response to 
temsirolimus. We also include a literature review summarizing the published experience with 
targeted therapeutic approaches in chromophobe RCC. Additionally, the preclinical rationale 
for the use of mTOR inhibitors in this population based on our characterization of the he-
reditary form of chromophobe kidney cancer, Birt-Hogg-Dube syndrome, is discussed. 
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Introduction 
Advances  in  our  understanding  of  the  genetic 
alterations underlying clear cell renal cell carcinoma 
(RCC)  has  led  to  a  proliferation  of  clinically  active 
agents for this disease, and since 2005, a total of seven 
agents  (sorafenib,  sunitinib,  temsirolimus,  bevaci-
zumab,  everolimus,  pazopanib,  and  axitinib)  have 
been approved for the treatment of metastatic kidney 
cancer. While kidney cancer was once considered to 
be a single entity, extensive research over the past 3 
decades has resulted in classification of RCC into dis-
tinct subtypes based on disparate genetic and molec-
ular  alterations.  Most  of  the  FDA  approved  agents 
have been tested in a fairly uniform patient popula-
tion with predominantly clear cell tumors. Extrapo-
lating the benefit of these agents to the other common 
subtypes  of  kidney  cancer  including  papillary  and 
chromophobe tumors, while common in clinical prac-
tice, is not supported by robust scientific and clinical 
evidence. Thus, clinical trial participation should be 
encouraged for patients with non-clear cell histology, 
a recommendation endorsed by the NCCN.1 Several 
small phase II trials have looked at the use of targeted 
agents  in  the  patients  with  papillary  and  other 
non-clear cell variants of RCC and have not demon-
strated an overwhelming benefit.2,3  
The clinical utility of inhibitors of the VEGF or 
mTOR pathways in patients with chromophobe RCC 
remains unclear with limited evidence acquired from 
retrospective  analyses  and  expanded  access  trials. 
Choueiri  and  colleagues  described  their  experience 
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with  VEGF  pathway  antagonists  in  a  mul-
ti-institutional, retrospective series, reporting 3 partial 
responses  in  12  patients.4  Data  from  the  expanded 
access program for sorafenib also suggests some ac-
tivity in chromophobe RCC as 90% of patients (n=18) 
had  some  measure  of  disease  control  (1  partial  re-
sponse and 17 stable disease).5 For mTOR agents, the 
results are more uncertain with no large case series or 
prospective  studies  available.  Post  hoc  subgroup 
analysis  of  the  ARCC  study  with  temsirolimus 
demonstrated  a  potential  benefit  in  non-clear  cell 
RCC; however the incidence of chromophobe RCC in 
the non-clear group is not reported.6  
In order to better understand the potential role of 
mTOR,  we evaluated the literature and our institu-
tional experience with patients with metastatic chro-
mophobe RCC. Additionally we sought to better un-
derstand the burden of metastatic chromophobe RCC 
in the United States using the Surveillance Epidemi-
ology and End Result (SEER)-17 program. 
Methods 
We reviewed the literature for published reports 
of  chromophobe  RCC  treated  with  mTOR  therapy 
from  2006-2011.  Search  terms  included  “chromo-
phobe”  and  “kidney  cancer.”  All  manuscripts  were 
reviewed  for  patients  with  metastatic chromophobe 
RCC  who  had  received  systemic  „targeted  therapy‟ 
including  sirolimus,  everolimus,  or  temsirolimus. 
Reports selected had details outlining the agent used, 
indication, line of therapy, prior treatment, response, 
and patient outcome. Our institutional database was 
reviewed  to  determine  cases  of  metastatic  chromo-
phobe RCC from 2006-2011 treated with mTOR ther-
apy. Only one patient was identified and we reviewed 
the patient‟s presentation, surgical management, sys-
temic therapy, and clinical response.   
A brief review of the Surveillance Epidemiology 
and End Result (SEER)-17 program provided an es-
timate of the deaths due to chromophobe RCC each 
year. The SEER program now records cancer statistics 
from approximately 28% of the United States popula-
tion. From 2003 to 2008, all patients listed as having 
cancer of the kidney and renal pelvis were selected. 
Cases with ICD-O-3 histology codes believed to rep-
resent RCC (8140, 8260, 8270, 8290, 8310, 8312, 8316, 
8317-8320)  were  chosen  for  further  review.  Patients 
dying of RCC from 2003-2007 were reviewed to de-
termine the number of deaths attributed to chromo-
phobe RCC (histology codes 8270 and 8317). The an-
nual death rates per 100,000 was calculated for RCC 
overall  and  for  chromophobe  histology  using 
SEER*Stat (Version 7.05). 
 
Results 
Case Report 
Review of our institutional database revealed a 
single  patient  with  metastatic  chromophobe  RCC 
treated with targeted therapy. In February, 2000, a 45 
year-old woman presented with fatigue, weight loss, 
and a large palpable abdominal mass. A CT scan of 
the abdomen demonstrated an 18 cm left renal mass 
(Figure  1).  She  underwent  a  left  sided  radical  ne-
phrectomy  and  final  pathology  demonstrated  a  T2, 
chromophobe renal cell carcinoma (RCC) with areas 
of  sarcomatoid  transformation.  She  was  followed 
closely  with  periodic  surveillance  and  was  free  of 
disease for 6 years. In June 2006, she presented with 
multiple small liver nodules; laparoscopic resection of 
a hepatic lesion confirmed the presence of metastatic 
chromophobe RCC. Once recovered, she was placed 
on  sunitinib  (50mg  orally  on  a  four-weeks  on, 
two-weeks off schedule) and had regression in some 
of the liver lesions.  
Following five cycles (approximately 7 months), 
she demonstrated progressive disease, with enlarge-
ment  of  several  liver  lesions  (largest  approximately 
2.5 cm). Sunitinib was discontinued after June of 2007 
and  temsirolimus  was  recommended  (25mg/kg  IV 
every week). The patient was unable to promptly ini-
tiate  therapy  and  started  temsirolimus  around  the 
time of repeat imaging in October 2007 at which time 
the largest liver lesion had increased to 3.2 cm. On 
therapy, multiple liver lesions regressed, and the pa-
tient achieved a partial response per RECIST. In Feb-
ruary 2008, a chest CT obtained for restaging revealed 
mild interstitial changes. However, the patient had no 
accompanying  symptoms  and  pulmonary  function 
testing was normal; temsirolimus was therefore con-
tinued  with  close  monitoring  for  respiratory  symp-
toms.  
During the next two years the liver lesions re-
mained stable on therapy. However, in August, 2009, 
she developed several small bilateral sub-centimeter 
pulmonary nodules, consistent with lung metastases. 
Bevacizumab was added to temsirolimus at that time. 
In  June,  2010  she  developed  significant  proteinuria 
and bevacizumab was discontinued. Fortunately, the 
lung and liver lesions have remained fairly stable with 
minimal interval growth of some lesions. Currently, 
she  remains  on  temsirolimus  with  excellent  perfor-
mance status, alive 5 years after the development of 
metastatic disease. Figure 2 summarizes her treatment 
history and clinical course.   Journal of Cancer 2012, 3 
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Figure 1: CT scan with IV contrast demonstrating the 18 cm left renal tumor prior to radical nephrectomy in 2002. 
 
 
Figure 2: Treatment history and total disease progression calculated by summation of maximal dimension of all measurable lesions (>1 
cm) in axial imaging (RECIST). (*Small lung nodules noted on chest imaging). (^ Appearance of measurable lung nodules). 
 
 
Published Reports 
In the past year, a small number of interesting 
case  reports  have  described  the  activity  of  mTOR 
agents  in  chromophobe  RCC  (Table  1).7-9  The  first 
report  from  Paule  and  colleagues  described  a  57 
year-old  man  who  had  an  early  retroperitoneal  re-
currence  after  a  left  radical  nephrectomy  for  a  T2 
Fuhrman grade 2-3 chromophobe RCC.8 The patient 
had  initial  treatment  with  subcutaneous  Interfer-
on-alpha  followed  by  sorafenib  but  eventually  pro-
gressed. Temsirolimus therapy lead to disease stabi-
lization for 26 months and the patient had a partial 
resection of the retroperitoneal mass. The patient re-
sumed therapy and remained on treatment for over 
two years. The last imaging study showed a signifi-
cant response of the residual retroperitoneal mass per 
author assessment.   Journal of Cancer 2012, 3 
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Zardavas  and  colleagues  report  a  case  of  a  27 
year-old  female  who  underwent  a  radical  nephrec-
tomy for a T2N1M0 chromophobe RCC.9 The patient 
presented three years later with metastatic disease in 
the  liver  and  received  sunitinib  and  then  sorafenib 
therapy  without  an  objective  response.  The  patient 
was  placed  on  temsirolimus  and  had  a  partial  re-
sponse  by  RECIST  criteria  and  remains  on  therapy 
after a year with excellent performance status. 
The final report from Larkin and colleagues de-
scribed  a  53  year-old  man  who  underwent  a  right 
radical nephrectomy for a 6 cm, T3a, Fuhrman grade 
III chromophobe RCC.7 The patient was found to have 
an unresectable retroperitoneal recurrence three years 
later and was placed on sunitinib. After a partial re-
sponse the patient was taken off therapy for unrelated 
medical issues. Everolimus was started and the pa-
tient experienced a partial response by RECIST crite-
ria, still remaining on mTOR therapy after 2 years.  
SEER Population Estimates 
From 2003-2008, the annual adjusted death rate 
per  100,000  persons  for  RCC  overall  ranged  from 
2.670 to 3.091. For chromophobe histology, the death 
rate was extremely low, ranging from 0.015 to 0.034 
per 100,000 persons (Figure 3A). The number of SEER 
cases  of  deaths  from  chromophobe  RCC  identified 
was  between  4-9  cases/year  and  accounted  for  ap-
proximately 1% of total deaths from RCC (Figure 3B). 
As SEER data relies on medical extraction, the num-
bers may have some inaccuracies. However, based on 
this data, the number of total chromophobe deaths a 
year in the US population would be roughly 14-32 per 
year. 
Discussion 
Unlike  clear  cell  RCC,  the  natural  history  of 
metastatic chromophobe RCC is not well character-
ized and therefore, it may be difficult to quantify the 
therapeutic  benefit  associated  with  targeted  thera-
peutic agents in this population. Several series inves-
tigate the survival  of patients with metastatic chro-
mophobe RCC and survival appears to vary widely 
with median survival ranging from 7 to 29 months. 
10,11  The  low  incidence  of  metastatic  chromophobe 
RCC, the limited insight into disease biology, and the 
fact that most targeted agents were mainly developed 
for and evaluated in patients with clear cell RCC are 
some factors that make characterization of the natural 
history  and  development  of  a  standard  therapeutic 
approach for this condition challenging.12  
A better understanding of the biology of chro-
mophobe  RCC  can  enhance  our  ability  to  develop 
rational  targeted  strategies  directed  against  specific 
pathways thought to contribute to this disease. Un-
derstanding  the  biochemical  consequences  of  VHL 
loss in hereditary and subsequently, sporadic forms of 
clear cell RCC was a critical step in the development 
of  both  VEGF-  and  mTOR-pathway  antagonists.13 
Similarly, emerging data from studies of a hereditary 
form of chromophobe RCC, the Birt-Hogg-Dube syn-
drome (BHD), may shed light on the biology of the 
sporadic form of the disease.  
 
 
Table 1: mTOR agents in metastatic chromophobe RCC: Summary of case reports. 
 
Abbreviations: NR- not reported, SD- syable disease, PR, partial response, M1- metastatic disease. 
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Figure 3. A: Annual death rate for RCC overall (red) and Chromophobe histology (Blue) from 2003-2008. Rate is per 100,000 persons 
and is age-adjusted to the US population in 2000. Note log scale. B: Percentage of RCC Deaths attributed to Chromophobe RCC 
histology from 2003-2008. 
 
 
Patients with BHD are at risk for the develop-
ment of bilateral, multifocal renal tumors and have 
germline  inactivating  mutations  in  the  FLCN  gene. 
Hasumi and colleagues from our institution demon-
strated  that  folliculin  loss  leads  to  development  of 
tumors  with  highly  active  PI3K/mTOR  pathways.1 
Baba and colleagues have demonstrated that mTOR 
inhibition with rapamycin could reverse the pheno-
type of polycystic kidneys and renal failure in a con-
ditional FLCN knockout mouse model.14 Although the 
role of folliculin in non-hereditary forms of chromo-
phobe RCC remains to be fully elucidated, these data 
provide a reasonable basis for the evaluation of the 
mTOR  pathways  and  inhibitors  of  the 
PI3K/Akt/mTOR axis in chromophobe RCC.   Journal of Cancer 2012, 3 
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Moving forward, it may be nearly impossible to 
conduct  a  large  randomized  trial  with  metastatic 
chromophobe patients due to the rarity of this disease, 
as demonstrated by our SEER analyses. A reasonable 
approach might be to investigate agents whose use in 
chromophobe RCC is supported by preclinical stud-
ies,  in  carefully  designed,  well-coordinated  mul-
ti-center phase 2 studies.  Studies including patients 
with all types of non-clear cell histologies may also 
provide  insight,  as  long  as  subtype  stratification  is 
performed. One such trial, ASPEN, a phase II trial of 
everolimus vs. sunitinib in metastatic, non-clear cell 
tumors,  may  provide  some  data  on  the  activity  of 
these  agents  in  chromophobe  RCC  (NCI  Trial  ID: 
NCT01108445). 
In  conclusion,  we  support  the  evaluation  of 
mTOR-directed  therapy  in  chromophobe  RCC  with 
cautious enthusiasm; this approach is supported by 
both  interesting  anecdotal  evidence  and  preclinical 
rationale. Due to the rarity of this disease, uncertainty 
about the biology and disease course, and lack of a 
coordinated approach to the management of this and 
other rare entities, there are many unanswered ques-
tions. We hope institutions across the globe will work 
together to determine the optimal systemic treatment 
for this challenging kidney cancer population. 
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